Wei Li

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network

Yawei Zhang, Qi Wang, Yuyao Yin et al. · Antimicrobial Agents and Chemotherapy · 2017 · 446 citations · Full text

Blocked Signal Transduction to the ERK and JNK Protein Kinases in Anergic CD4 ⁺ T Cells

Wei Li, Carmella D. Whaley, Anna Mondino et al. · Science · 1996 · 426 citations

Jnk Protein Kinases, T-regulatory Cell, Immunology +20

VEGF Prevents Apoptosis of Human Microvascular Endothelial Cells via Opposing Effects on MAPK/ERK and SAPK/JNK Signaling

Kalpna Gupta, Smita Kshirsagar, Wei Li et al. · Experimental Cell Research · 1999 · 380 citations

Vegf Prevents Apoptosis, Angiogenesis, Opposing Effects +12

Phenotypic and Genotypic Characterization of Carbapenem-resistant<i>Enterobacteriaceae</i>: Data From a Longitudinal Large-scale CRE Study in China (2012–2016)

Qi Wang, Xiaojuan Wang, Juan Wang et al. · Clinical Infectious Diseases · 2018 · 348 citations · Full text